Investors Review: Research in Motion Ltd, VMware, Amicus Therapeutics, Trius Therapeutics

Dallas, TX -- (SBWIRE) -- 03/14/2013 -- Marketbuzzreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Research In Motion Ltd (NASDAQ:BBRY) shares increased 8.17% to $15.65 after the company yesterday announced that it has received a purchase order for 1 million BlackBerry 10 devices – the biggest single order in the history of BlackBerry. The company didn’t reveal the name of the company or the model which was ordered. But it did state that the order was from one of its “established partners.” The company said its partner has asked to start shipments immediately.

How Should Investors Trade BBRY After The Recent Price movement? Find out Here

VMware, Inc. (NYSE:VMW) shares jumped 8.08% and closed at $81.37. The company, on Feb. 28, introduced the VMware vCloud for Healthcare solution supporting the IT care environment -- from point-of-care to the most critical patient-care systems. Leveraging VMware's extensive portfolio of products, services and healthcare industry expertise, vCloud for Healthcare enables healthcare organizations to move more confidently into the cloud, help achieve Stage 2 Meaningful Use and improve patient outcomes.

Is VMW a Strong Buying Opportunity After The Recent Slump? Find out Here

Amicus Therapeutics, Inc.(NASDAQ:FOLD) shares jumped 8.06% and closed at $3.35. The company, on Mar. 12, announced financial results for the full-year ended December 31, 2012. The Company also summarized recent and upcoming milestones and reiterated full-year 2013 operating expense guidance. The company posted full year 2012 total revenue of $18.4 million compared to $21.4 million for the full-year 2011. Full year net loss was $48.8 million, or $1.07 per share, compared to a net loss of $44.4 million, or $1.28 per share, for the full-year 2011.

Is FOLD a Buy After The Latest Price Action? Find Out Here

Trius Therapeutics, Inc.(NASDAQ:TSRX) Shares increased 7.89% to $6.70. The company on March 12, reported a net loss of $14.2 million versus a net loss of $12.5 million in the comparable period in 2011. For the year ended December 31, 2012, it reported a net loss of $53.9 million compared to $18.3 million for the same period in 2011. Revenues for the three months ended December 31, 2012 were $5.2 million compared to $5.0 million for the same period in 2011. For the year ended December 31, 2012, revenues were $27.2 million compared to $41.0 million for the same period in 2011.

Is TSRX a Buy After The Latest Price Action? Find Out Here

About Marketbuzzreport.com
Marketbuzzreport.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Marketbuzzreport.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.marketbuzzreport.com

Disclaimer
The assembled information disseminated by Marketbuzzreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Marketbuzzreport.com does expect that investors will buy and sell securities based on information assembled and presented in Marketbuzzreport.com. PLEASE always do your own due diligence, and consult your financial advisor.